(Revised 12/5/03) Horse owners have a new option for treating equine protozoal myeloencephalitis (EPM) following the Nov. 19 U.S. Food and Drug Administration's (FDA) approval of nitazoxanide. This medication has been under development as an EPM treatment for more than six years.

IDEXX Laboratories of Westbrook, Maine, received approval for the product, called Navigator, whic

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In
Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners